FDA's Thinking On New Psychiatric Endpoints: What Does Brintellix CRL Portend For Nuplazid?
FDA deviated from its advisory committee's recommendation on the first cognitive function claim for an antidepressant when it issued a complete response letter for Brintellix. The decision could signal trouble for Acadia's Nuplazid for Parkinson's psychosis, which also relies on a new psychiatric endpoint.
You may also be interested in...
Alkermes revealed successful completion of its third Phase III trial for the depression drug ALKS 5461 as well as a risky plan to seek FDA approval based on two negative and one positive late-stage study.
Rigorous planning and a multidisciplinary team including database experts and healthcare specialists with local knowledge are vital to effective real-world evidence, white paper shows.
The latest submission and expedited review program news and highlights from our US FDA Performance Tracker.